Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This outcome has already been shown in preclinical studies that have demonstrated notable advantages of Skye’s lead therapeutic drug, SBI-100 Ophthalmic Emulsion (Tetrahydrocannabinol), over the established clinical standard of care for treating glaucoma.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Ophthalmology Product Name: SBI-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Skye Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 12, 2022